1. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 Does not lead to a "typical" acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020; 201:1299–300.
Article
2. Riva CM, Morganroth ML, Ljungman AG, Schoeneich SO, Marks RM, Todd RF 3rd, et al. Iloprost inhib-its neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers. Am J Respir Cell Mol Biol. 1990; 3:301–9.
Article
3. Gu SX, Tyagi T, Jain K, Gu VW, Lee SH, Hwa JM, et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol. 2021; 18:194–209.
Article
4. Sonti R, Pike CW, Cobb N. Responsiveness of inhaled epoprostenol in respiratory failure due to COVID-19. J Intensive Care Med. 2021; 36:327–33.
Article
5. Tsareva NA, Avdeev SN, Kosanovic D, Schermuly RT, Trushenko NV, Nekludova GV. Inhaled iloprost improves gas exchange in patients with COVID-19 and acute respiratory distress syndrome. Crit Care. 2021; 25:258.
Article